A 28-year-old woman with severe, generalized atopic dermatitis refractory to high-potency topical corticosteroids and calcineurin inhibitors for 3 months seeks treatment. Systemic therapy is indicated. Which is the preferred first-line systemic agent in current practice?

Explanation

## Systemic Therapy for Severe Refractory Atopic Dermatitis **Key Point:** Dupilumab, a biologic monoclonal antibody targeting IL-4 receptor-α, is now the preferred first-line systemic agent for severe atopic dermatitis refractory to topical therapy. ### Mechanism and Clinical Efficacy of Dupilumab 1. **Target**: Blocks IL-4 receptor-α, inhibiting both IL-4 and IL-13 signaling—key drivers of Th2-mediated inflammation in AD. 2. **Efficacy**: Achieves 50–75% improvement in EASI (Eczema Area and Severity Index) scores in 60–70% of patients. 3. **Onset**: Rapid clinical improvement within 2–4 weeks. 4. **Safety**: Well-tolerated; no systemic immunosuppression or organ toxicity monitoring required. 5. **Approval**: FDA-approved (2017) and increasingly available in India for severe AD. ### Comparison of Systemic AD Therapies | Agent | Mechanism | Onset | Efficacy | Monitoring | Adverse Effects | Role | |-------|-----------|-------|----------|-----------|-----------------|------| | **Dupilumab** | Anti-IL-4Rα (biologic) | 2–4 weeks | Excellent (60–75%) | Minimal | Mild (conjunctivitis, injection site reaction) | **First-line systemic** | | **Oral prednisolone** | Broad immunosuppression | 1–2 weeks | Good short-term | BP, glucose, bone | Rebound flare, steroid dependence, long-term toxicity | Avoid; only short-term bridge | | **Azathioprine** | Purine antagonist | 6–8 weeks | Moderate | CBC, LFTs, TPMT | Myelosuppression, infection risk | Second-line alternative | | **Methotrexate** | Antimetabolite | 4–6 weeks | Moderate | CBC, LFTs, renal | Hepatotoxicity, myelosuppression, teratogenicity | Second-line alternative | ### Why Dupilumab Is Preferred ```mermaid flowchart TD A[Severe AD refractory to topical therapy]:::outcome --> B{Systemic therapy indicated}:::decision B --> C{First-line choice?}:::decision C -->|Biologic available| D[Dupilumab]:::action C -->|Biologic unavailable/contraindicated| E[Azathioprine or Methotrexate]:::action D --> F[IL-4Rα blockade]:::outcome F --> G[Rapid Th2 suppression]:::outcome G --> H[Clinical remission in 60-75%]:::outcome E --> I[Slower onset, more monitoring]:::outcome ``` **High-Yield:** Dupilumab is now the gold standard first-line systemic agent for severe AD because it targets the pathogenic Th2 axis directly, has rapid onset, excellent efficacy, and minimal systemic toxicity. It has largely replaced older immunosuppressants as first-line in guidelines (AAD, EADV, IADVL 2023). **Clinical Pearl:** Dupilumab is administered as a loading dose (600 mg SC), followed by 300 mg SC every 2 weeks. Response is typically evident by 4 weeks; if inadequate, continue for 12 weeks before switching agents. **Warning:** Do NOT use oral prednisolone as first-line systemic therapy—it causes rebound flares upon tapering and carries long-term steroid toxicity risks (osteoporosis, infection, metabolic complications).